Literature DB >> 9744456

Parathyroidectomy via bilateral cervical exploration: a retrospective review of 866 cases.

R A Low1, A D Katz.   

Abstract

INTRODUCTION: Parathyroidectomy via cervical exploration is an effective primary-modality treatment for hyperparathyroidism, with cure rates of greater than 95%. We retrospectively reviewed 866 consecutive parathyroidectomies performed by a single surgeon between 1960 and 1997. We attempted to describe the polymorphic variation in multiglandular disease, the anatomic locations of pathologic glands, and the operative strategy and techniques which we believed were important to minimizing morbidity and maximizing curative success.
METHODS: The cases of 329 males and 537 females (age, 1-88 years) were reviewed. There were 766 operations performed: primary hyperparathyroidism (713), tertiary hyperparathyroidism (100), reoperations (53). The strategy for primary exploration includes a bilateral neck exploration, early recurrent laryngeal nerve skeletonization, and identification of at least four glands.
RESULTS: Normocalcemia was achieved in 98.2% of cases after initial cervical exploration. Persistent hypercalcemia occurred in 7 patients (<1%). Nine patients (1%) suffered persistent postoperative hypocalcemia. Unilateral recurrent laryngeal nerve injury occurred in two patients (<1%). Other perioperative complications included: reoperation for hematoma, repaired carotid artery injury, unexplained dysphagia, pneumothorax, deep venous thrombosis, and aspiration pneumonia. There were two mortalities (<1%) attributable to severe, comorbid disease. Ectopic glands were found in 120 cases. The frequency of glands at these sites were as follows: mediastinal (4.9%), intrathymic (8.4%), intrathyroid (6.7%), and retroesophageal/retrotracheal (3.5%). Thyroid resections provided diagnosis of concomitant thyroid carcinoma in 8.0% of resected patients. The pathology of patients with primary hyperparathyroidism (PHPT) consisted of single adenomas (77.2%), hyperplasia (21.0%), normal glands (1%), double adenomas (<1%), and parathyroid carcinoma (<1%). The distribution of adenomas was as follows: left upper, 25.3%; left lower, 27.3%; right upper, 26.8%; right lower, 20.6%. Hyperplastic glands were found in ectopic positions as follows: intrathymic (7.5%), intrathyroid (11.3%), mediastinal (2.5%), and retroesophageal/retrotracheal (0%). The average volume difference between the largest and smallest hyperplastic gland of each case was 1.80 + 4.40 cm3. Reoperations were performed upon 53 referred patients and 7 patients after failed exploration. Normocalcemia was attained in 98.3% of cases. Glandular pathology was identified in the previous operative field in 52 patients (86.7%). Adenomas were identified in 56.0% (n = 23) and hyperplasia in 39.0% (n = 16).
CONCLUSIONS: In our series, we were able to attain normocalcemia in 98.2% of cases after initial cervical exploration. We believe that identification of four glands, an exhaustive search of ectopic sites, bilateral exploration, and liberal use of biopsy and intraoperative frozen section were essential to curative success. The pathologist should identify parathyroid tissue in the specimen and differentiate the "abnormal" from "normal" gland. Morphologic criteria alone cannot be used because of polymorphic variation in hyperplasia in which pathologic glands may appear normal. Early identification of the recurrent laryngeal nerve allows for a safer neck exploration by alerting the surgeon to the location and course of the nerve. A bilateral approach does not contribute increased morbidity from recurrent laryngeal nerve injury.

Entities:  

Mesh:

Year:  1998        PMID: 9744456     DOI: 10.1002/(sici)1097-0347(199810)20:7<583::aid-hed1>3.0.co;2-x

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  16 in total

Review 1.  [Reoperation for primary hyperparathyroidism].

Authors:  E Karakas; A Zielke; C Dietz; M Rothmund
Journal:  Chirurg       Date:  2005-03       Impact factor: 0.955

2.  The outcome of cervical exploration for asymptomatic and symptomatic patients with primary hyperparathyroidism.

Authors:  Jaber S Abbas; Suzan I Hashem; Walid G Faraj; Mohammad J Khalifeh; Mukbil H Horani; Ibrahim S Salti
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

Review 3.  Best practice no 183. Examination of parathyroid gland specimens.

Authors:  S J Johnson; E A Sheffield; A M McNicol
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

4.  MR appearance of parathyroid adenomas at 3 T in patients with primary hyperparathyroidism: what radiologists need to know for pre-operative localization.

Authors:  B Sacconi; R Argirò; Daniele Diacinti; A Iannarelli; M Bezzi; C Cipriani; D Pisani; V Cipolla; C De Felice; S Minisola; C Catalano
Journal:  Eur Radiol       Date:  2015-05-31       Impact factor: 5.315

5.  Minimally invasive parathyroid surgery.

Authors:  G M Fuhrman; J S Bolton
Journal:  Ochsner J       Date:  2000-07

6.  Improved success rate in reoperative parathyroidectomy with intraoperative PTH assay.

Authors:  G L Irvin; A S Molinari; C Figueroa; D M Carneiro
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

7.  Rapid intraoperative parathyroid hormone assay--more than just a comfort measure.

Authors:  F Hanif; J C Coffey; L Romics; K O'Sullivan; F Aftab; H P Redmond
Journal:  World J Surg       Date:  2006-02       Impact factor: 3.352

Review 8.  Hyperparathyroidism in the elderly patient.

Authors:  Rebecca Sims; Charanjeit Ubhi; David Hosking
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  Minimally invasive video-assisted parathyroidectomy versus open minimally invasive parathyroidectomy for a solitary parathyroid adenoma: a prospective, randomized, blinded trial.

Authors:  Marcin Barczyński; Stanisław Cichoń; Aleksander Konturek; Wojciech Cichoń
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

10.  Minimally invasive parathyroidectomy with or without intraoperative parathyroid hormone for primary hyperparathyroidism.

Authors:  Hyun Gu Kim; Woo Young Kim; Sang Uk Woo; Jae Bok Lee; Yu-Mi Lee
Journal:  Ann Surg Treat Res       Date:  2015-08-24       Impact factor: 1.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.